crisaborole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5201	906673-24-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: staquis crisaborole AN2728 eucrisa	Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined. Molecular weight: 251.05 Formula: C14H10BNO3 CLOGP: 2.63 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 62.48 ALOGS: -4.03 ROTB: 2 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

staquis
crisaborole
AN2728
eucrisa

Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.

Molecular weight: 251.05
Formula: C14H10BNO3
CLOGP: 2.63
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 62.48
ALOGS: -4.03
ROTB: 2

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 27, 2020	EMA	Pfizer Europe MA EEIG
Dec. 14, 2016	FDA	ANACOR PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pain	2118.81	71.76	330	2471	3468	50598855
Burning sensation	702.67	71.76	204	2597	45242	50557081
Application site erythema	258.49	71.76	58	2743	4480	50597843
Drug ineffective	146.55	71.76	200	2601	819133	49783190
Application site pruritus	134.59	71.76	33	2768	3726	50598597
Skin burning sensation	127.06	71.76	39	2762	10146	50592177
Drug effective for unapproved indication	127.05	71.76	28	2773	1981	50600342
Dermatitis atopic	115.89	71.76	29	2772	3557	50598766
Application site swelling	111.84	71.76	20	2781	478	50601845
Condition aggravated	94.59	71.76	98	2703	296960	50305363
Eyelid irritation	90.17	71.76	16	2785	365	50601958
Drug ineffective for unapproved indication	88.51	71.76	36	2765	21245	50581078
Eczema	86.26	71.76	36	2765	22666	50579657
Product use in unapproved indication	76.63	71.76	58	2743	115761	50486562

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pain	1143.65	166.29	166	1014	1513	29571834
Burning sensation	400.46	166.29	98	1082	15840	29557507
Application site erythema	176.84	166.29	35	1145	2064	29571283
Drug ineffective	166.52	166.29	126	1054	363044	29210303

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pain	2084.04	77.77	323	2687	3925	64491797
Burning sensation	611.10	77.77	180	2830	49484	64446238
Application site erythema	352.23	77.77	73	2937	4616	64491106
Drug ineffective	309.47	77.77	275	2735	839972	63655750
Application site pruritus	180.02	77.77	40	2970	3499	64492223
Condition aggravated	145.00	77.77	127	2883	372299	64123423
Dermatitis atopic	118.56	77.77	29	2981	3847	64491875
Drug ineffective for unapproved indication	111.26	77.77	45	2965	31088	64464634
Skin burning sensation	106.34	77.77	33	2977	10550	64485172
Application site swelling	97.25	77.77	18	2992	624	64495098
Eczema	96.11	77.77	40	2970	29680	64466042
Pruritus	94.95	77.77	93	2917	312307	64183415
Off label use	86.43	77.77	125	2885	632681	63863041
Erythema	85.08	77.77	70	2940	187000	64308722
Application site irritation	81.13	77.77	18	2992	1558	64494164

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D11AH06	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids
FDA MoA	N0000182960	Phosphodiesterase 4 Inhibitors
FDA EPC	N0000182961	Phosphodiesterase 4 Inhibitor
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50748	antipsoriatic drug
CHEBI has role	CHEBI:68844	phosphodiesterase IV inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.8	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	8501712	Feb. 16, 2027	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	9682092	Feb. 16, 2027	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	8168614	Jan. 20, 2030	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	June 14, 2022	PEDIATRIC EXCLUSIVITY
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	March 23, 2023	NEW PATIENT POPULATION
2%	EUCRISA	ANACOR PHARMS INC	N207695	Dec. 14, 2016	RX	OINTMENT	TOPICAL	Sept. 23, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Phosphodiesterase 4	Enzyme	P27815 Q07343 Q08493 Q08499	PDE4A_HUMAN PDE4B_HUMAN PDE4C_HUMAN PDE4D_HUMAN	INHIBITOR	IC50	6.31	SCIENTIFIC LITERATURE	DRUG LABEL
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Enzyme	P54750	PDE1A_HUMAN		IC50	5.21	CHEMBL
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	Enzyme	Q13946	PDE7A_HUMAN		IC50	6.14	CHEMBL

External reference:

ID	Source
Q2R47HGR7P	UNII
C4301781	UMLSCUI
CHEBI:134677	CHEBI
CHEMBL484785	ChEMBL_ID
44591583	PUBCHEM_CID
DB05219	DRUGBANK_ID
D10873	KEGG_DRUG
9151	IUPHAR_LIGAND_ID
1865953	RXNORM
248463	MMSL
32196	MMSL
724007009	SNOMEDCT_US
763593001	SNOMEDCT_US
4036360	VANDF
017053	NDDF
C543085	MESH_SUPPLEMENTAL_RECORD_UI
10024	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Staquis	HUMAN PRESCRIPTION DRUG LABEL	1	0009-2211	OINTMENT	20 mg	TOPICAL	EXPORT ONLY	1 sections
Eucrisa	HUMAN PRESCRIPTION DRUG LABEL	1	55724-211	OINTMENT	20 mg	TOPICAL	NDA	27 sections